Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R; 308 Study Group. Bergallo C, et al. Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61. doi: 10.1016/j.diagmicrobio.2008.09.001. Epub 2008 Nov 5. Diagn Microbiol Infect Dis. 2009. PMID: 18990531 Clinical Trial.
Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia.
Stryjewski ME, Barriere SL, Rubinstein E, Genter FC, Lentnek AL, Magana-Aquino M, Luna CM, Niederman MS, Torres A, Corey GR. Stryjewski ME, et al. Among authors: lentnek al. Int J Antimicrob Agents. 2013 Oct;42(4):367-9. doi: 10.1016/j.ijantimicag.2013.06.003. Epub 2013 Jul 26. Int J Antimicrob Agents. 2013. PMID: 23891527 No abstract available.
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME; ATTAIN Study Group. Rubinstein E, et al. Among authors: lentnek al. Clin Infect Dis. 2011 Jan 1;52(1):31-40. doi: 10.1093/cid/ciq031. Clin Infect Dis. 2011. PMID: 21148517 Free PMC article. Clinical Trial.
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Stryjewski ME, et al. Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896. Clin Infect Dis. 2008. PMID: 18444791 Clinical Trial.
Nitazoxanide for the treatment of Clostridium difficile colitis.
Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, Rossignol JF. Musher DM, et al. Clin Infect Dis. 2006 Aug 15;43(4):421-7. doi: 10.1086/506351. Epub 2006 Jul 11. Clin Infect Dis. 2006. PMID: 16838229 Clinical Trial.
Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group. Louie TJ, et al. N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812. N Engl J Med. 2011. PMID: 21288078 Free article. Clinical Trial.
33 results